ABSTRACT
This chapter discusses the myriad and diversity of biotechnology products besides proteins number over 180, including peptides, vaccines, liposomes, oligonucleotides, polymers, cell therapies, and tissue therapies. Vaccines in biotechnology have become a major focus for the pharmaceutical and biotechnology industries based on the surge in infections that can be prevented, the antigen drift of the viral organisms, the huge base of patients needing therapy, and the financial opportunity for companies. Many biological products have been and are developed by traditional methods, distinct from biotech products from recombinant proteins and monoclonal antibodies from hybridoma technology. Anti-hemophilia products are still derived from blood. An anti-globulin is produced for kidney transplant rejection. Several newer products have been developed for hereditary angioedema. Fibrin sealants are created to stop intra-surgical bleeding. Progenitor blood cells are obtained for stem cell transplants used with cancer chemotherapy.
